Elizabeth Wong

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 456 citations · Full text

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 426 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Active Cyclooxygenase-2 Inhibitor +10

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

Denis Riendeau, M. David Percival, S. Boyce et al. · British Journal of Pharmacology · 1997 · 326 citations · Full text

Pge2 Production, Chemoprevention Strategy, Immunology +16

5‐lipoxygenase‐activating protein is an arachidonate binding protein

Joseph A. Mancini, Mark Abramovitz, Martha E. Cox et al. · FEBS Letters · 1993 · 228 citations · Full text

Proteinlipid Interaction, Signal Transduction, Biochemistry +11

5‐Lipoxygenase‐activating protein stimulates the utilization of arachidonic acid by 5‐lipoxygenase

Mark Abramovitz, Elizabeth Wong, Martha E. Cox et al. · European Journal of Biochemistry · 1993 · 212 citations · Full text

Biosynthesis, Molecular Physiology, Cellular Enzymology +15